PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
Volume 5.25M
Average 1.04M
PDSB Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
PDS Biotechnology CorporationNASDAQ: PDSB
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 45.8% from a year ago
Cash & equivalents stood at $21.66M at the end of Q1 FY2026, down 45.8% from a year earlier and down 18.9% from the prior quarter. Over 3 fiscal years it compounded at -28.7% a year.
Context
- Cash & equivalents amounted to 87.8% of total assets at the end of Q1 FY2026, up 2.8 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -45.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 26.71M USD
- Year-over-year change
- -35.9%
- 4-year CAGR
- -20.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.71M | -35.9% |
| FY2024 | 2024-12-31 | 41.69M | -26.3% |
| FY2023 | 2023-12-31 | 56.56M | -23.4% |
| FY2022 | 2022-12-31 | 73.82M | +13.1% |
| FY2021 | 2021-12-31 | 65.24M | — |
Cash & Equivalents vs competitors
How PDSB compares with its peers on the latest reported figures
- PDSB's Mar 2026 cash & equivalents of $21.66M is the 4th highest of the 6 companies compared; the peer median is $36.47M.
- Its year-over-year change of -45.8% is the lowest of 6, against a peer median of +10.5%.
- Cash & equivalents amounts to 87.8% of total assets for PDSB, versus a peer median of 90.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
OKUROnKure Therapeutics, Inc. | Mar 2026 | $192.11M | +98.7% | +72.3% | 96.7% |
| Mar 2026 | $150.33M | +68.8% | +4.5% | 92.0% | |
| Jun 2026 | $36.47M | -39.1% | -23.9% | 90.8% | |
| Mar 2026 | $21.66M | -45.8% | -28.7% | 87.8% | |
| Mar 2026 | $21.36M | +10.5% | -22.0% | 82.7% | |
| Mar 2026 | $14.22M | -36.1% | -11.7% | 87.5% | |
| Peer median (excluding PDSB) | $36.47M | +10.5% | -11.7% | 90.8% | |
Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 65.24M | 73.82M | 56.56M | 41.69M | 26.71M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.66M | 2.49M | 3.36M | 1.54M |
| Total Current Assets | 66.84M | 76.48M | 59.06M | 45.05M | 28.25M |
| Property, Plant & Equipment (Net) | 357.7K | 527.53K | 335.01K | 304.21K | 243.7K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 2M |
| Total Non-current Assets | 357.7K | 527.53K | 335.01K | 304.21K | 2.24M |
| Total Assets | 67.2M | 77.01M | 59.39M | 45.36M | 30.49M |
| Account Payables | 1.31M | 1.22M | 6.98M | 1.68M | 3.57M |
| Short-term Debt | 0 | 0 | 4.17M | 12.5M | 5.13M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 729.39K | 1.84M | 1.29M | 663.4K | 271.74K |
| Total Current Liabilities | 3.76M | 9.82M | 13.63M | 17.09M | 9.48M |
| Long-term Debt | 0 | 23.02M | 19.51M | 9.2M | 11.73M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 231.43K | 23.18M | 19.63M | 9.27M | 11.76M |
| Total Liabilities | 3.99M | 33.01M | 33.26M | 26.35M | 21.24M |
| Common Stock | 9.39K | 9.96K | 10.92K | 12.54K | 18.11K |
| Retained Earnings | (60.7M) | (101.56M) | (144.5M) | (182.11M) | (216.61M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 63.21M | 44M | 26.13M | 19M | 9.25M |
| Total Debt | 490.35K | 23.47M | 23.85M | 21.83M | 16.93M |
| Net Debt | (64.75M) | (50.35M) | (32.71M) | (19.86M) | (9.79M) |
PDS Biotechnology Corporation
NASDAQ:PDSB
Intrinsic Alpha fair value
Locked
Current Price
$0.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.